News

Month Year

Month Year

Nov 10, 2025

Eight out of 10 infants and newborns in Canada have access to RSV prevention with Beyfortus® this season
Nov 6, 2025

Rezurock® now covered in Quebec for people living with chronic graft-versus-host disease (GVHD)
Nov 3, 2025

Dupixent® approved in Canada as targeted therapy for chronic spontaneous urticaria (CSU)
Oct 22, 2025

Dupixent® (dupilumab injection) approved in Canada for adults with inadequately controlled Chronic Obstructive Pulmonary Disease (COPD)
Oct 21, 2025

Sanofi’s high-dose influenza vaccine demonstrates superior protection for older adults against hospitalization vs standard-dose
Jun 9, 2025

Sanofi Appoints James Guy as Country Lead, Canada and General Manager, Specialty Care
- Photos 1
May 14, 2025

Kevzara® approved in Canada for the treatment of adults with polymyalgia rheumatica (PMR)
May 5, 2025

Health Canada has granted approval for Tzield®, the first and only disease-modifying therapy in autoimmune type 1 diabetes in Canada
Apr 22, 2025

Sarclisa® approved in Canada for patients with newly diagnosed multiple myeloma (NDMM)
Mar 27, 2025

Media Update: Once-weekly ALTUVIIIO® approved in Canada for the treatment of adults, adolescents and children living with hemophilia A
Oct 28, 2024

Beyfortus® immunization to protect infants from RSV has begun
Sep 12, 2024

DUPIXENT® (dupilumab injection) approved in Canada for the treatment of children aged 1 year and older with eosinophilic esophagitis (EoE)
Jul 26, 2024

Fluzone® High-Dose Quadrivalent vaccine remains preferentially recommended to protect adults 65 years of age and older against influenza
Jul 25, 2024

Ontario Ministry of Health Announces a Universal Public Program with Beyfortus® this RSV Season
Jun 18, 2024

Sanofi Canada celebrates winners of the 2024 Biogenius Competition and awards fourth annual Biogenius Grants
- Photos 1
May 31, 2024

Quebec Ministry of Health Announces Universal Public Program with Beyfortus® this Upcoming RSV Season
May 30, 2024

SANOFI OPENS NEW ADVANCED VACCINES FACILITY, STRENGTHENING ITS COMMITMENT TO BIOMANUFACTURING IN CANADA
- Photos 1
May 21, 2024

The National Advisory Committee on Immunization recommends BEYFORTUS® to protect all infants against RSV
Apr 18, 2024

Quebec's INESSS recommends BEYFORTUS® for the prevention of RSV for all infants 8 months of age and younger(1)
Apr 16, 2024

Sanofi Canada invests $180M CAD to build and update infrastructure to minimize environmental footprint at its Toronto Campus by 50%
- Photos 1
Mar 19, 2024

2024 Sanofi Biogenius Canada Grants open for applications
- Photos 1
Feb 20, 2024

JDRF Canada and Sanofi Canada partner to raise awareness about autoimmune type 1 diabetes and the critical role of screening in its early detection
- Photos 1
Jan 30, 2024

Sanofi Canada is celebrating 110 years of innovative health solutions for Canadians
Jul 25, 2023

Sanofi Consumer Healthcare North America Earns B Corp Certification in Recognition of Environmental, Social Impact
Jul 17, 2023

Dupixent® (dupilumab injection) receives marketing authorization for prurigo nodularis

Show per page